Table 3.
Clinical trials of miR-therapeutics in human cancers.
| Drug Name (Company) | Therapeutic miR | Clinical trials gov. Identifier | Current Trial status | Cancer type |
|---|---|---|---|---|
| MesomiR-1 (TargomiRs) (EnGeneIC) | miR-16 mimic | NCT02369198 | Phase I (completed expected to enter phase II) |
Malignant pleural mesothelioma Non-small cell lung cancer |
| MRX34 (Mirna Therapeutics) | miR-34 mimic | NCT01829971 | Phase I (terminated due to immune-related toxicities and deaths) | Primary Liver Cancer Small cell lung cancer Lymphoma Melanoma Multiple Myeloma Renal Cell Carcinoma Non-small cell lung cancer |
| MRG-106 (miRagen Therapeutics) |
AntagomiR-155 | NCT02580552 | Phase I (recruitment completed) | Cutaneous T-cell Lymphoma Mycosis Fungoides Chronic Lymphocytic Leukemia Diffuse Large B-Cell Lymphoma ABC Subtype Adult T-Cell Leukemia/Lymphoma |
| MRG-106 (miRagen Therapeutics) |
AntagomiR-155 | NCT03713320 | Phase II (recruitment completed) | Cutaneous T-Cell Lymphoma/Mycosis Fungoides |